Current status and achievements of Polish transfusion medicine

Antoniewicz‐Papis, Jolanta; Brojer, Ewa; Fabijańska-Mitek, Jadwiga; Gierszon, Agnieszka; Grabarczyk, Piotr; Guz, Katarzyna; Kalińska, Aleksandra; Kopacz, Aneta; Korsak, Jolanta; Lachert, Elżbieta; Łętowska, Magdalena; Łopacz, Patrycja; Michalewska, Bogumiła; Mikołowska, Agata; Nowak, Jacek; Olszewski, Adam J.; Orzińska, Agnieszka; Pelc‐Kłopotowska, Monika; Pogłód, Ryszard; Radziwon, Piotr; Rosiek, Aleksandra; Stachurska-Skrodzka, Anna; Sulkowska, Ewa; Szczepiórkowski, Zbigniew M.; Uhrynowska, Małgorzata; Uszyńska-Kałuża, Beata; Wojciechowska, Beata

doi:10.5603/ahp.2021.0031

Cited by 11 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The source plasma from automated plasmapheresis was supplied by Blood Transfusion Centers. Donors qualified according to Polish legal regulations were recruited from among COVID-19 convalescents after a minimum of 14 days of the repeat negative NAT test or after at least 28 days of symptom disappearance or termination of (post-discharge) quarantine [10][11][12].…”

Section: Methodsmentioning

confidence: 99%

Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product

Lachert

Lasocka

Bielawski³

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

This study aims to characterize the intermediates, and the final product (FP) obtained during the production of human intramuscular hyperimmune gamma globulin anti-SARS-CoV-2 (hIHGG anti-SARS-CoV-2) and to determine its stability. Material and methods: hIHGG anti-SARS-CoV-2 was fractionated from 270 convalescent plasma donations with the Cohn method. Prior to fractionation, the plasma was inactivated (Theraflex MB Plasma). Samples were defined using enzyme immunoassays (EIA) for anti-S1, anti-RBD S1, and anti-N antibodies, and neutralization assays with SARS-CoV-2 (VN) and pseudoviruses (PVN, decorated with SARS-CoV-2 S protein). Results were expressed as a titer (EIA) or 50% of the neutralization titer (IC50) estimated in a four-parameter nonlinear regression model. Results: Concentration of anti-S1 antibodies in plasma was similar before and after inactivation. Following fractionation, the anti-S1, anti-RBD, and anti-N (total tests) titers in FP were concentrated approximately 15-fold from 1:4 to 1:63 (1800 BAU/mL), 7-fold from 1:111 to 1:802 and from 1:13 to 1:88, respectively. During production, the IgA (anti-S1) antibody titer was reduced to an undetectable level and the IgM (anti-RBD) titer from 1:115 to 1:24. The neutralizing antibodies (nAb) titer increased in both VN (from 1:40 to 1:160) and PVN (IC50 from 63 to 313). The concentration of specific IgG in the FP did not change significantly for 14 months. Conclusions: The hIHGG anti-SARS-CoV-2 was stable, with concentration up to approximately 15-fold nAb compared to the source plasma pool.

show abstract

Section: Methodsmentioning

confidence: 99%

Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product

Lachert

Lasocka

Bielawski³

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the 64 th ASH Meeting, Polish scientists presented 22 posters, and coauthored 72 other studies, among them 25 oral (including abstracts #1 and #LBA-6) and 47 poster presentations. This is proof of high activity, at both national and international levels, which is continuously evolving [1][2][3][4][5].…”

mentioning

confidence: 99%

Inspiration from American Society of Hematology Annual Meeting

Styczyński

2023

Acta Haematol Pol.

View full text Add to dashboard Cite

“…This will be followed by recommendations on MDS treatment to appear in the next issue of "Acta Haematologica Polonica" [3]. These recommendations are in line with our journal's policy of international cooperation in hematology [4][5][6][7][8][9][10].…”

mentioning

confidence: 99%

Progress in molecular profiling: new recommendations in myelodysplastic syndromes

Styczyński

2022

Acta Haematol Pol.

View full text Add to dashboard Cite

Current status and achievements of Polish transfusion medicine

Cited by 11 publications

References 35 publications

Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product

Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2—Characteristics of Intermediates and Final Product

Inspiration from American Society of Hematology Annual Meeting

Progress in molecular profiling: new recommendations in myelodysplastic syndromes

Contact Info

Product

Resources

About